GB201506663D0 - In-vivo delivery of ion chelating ligands for therapy - Google Patents
In-vivo delivery of ion chelating ligands for therapyInfo
- Publication number
- GB201506663D0 GB201506663D0 GBGB1506663.2A GB201506663A GB201506663D0 GB 201506663 D0 GB201506663 D0 GB 201506663D0 GB 201506663 A GB201506663 A GB 201506663A GB 201506663 D0 GB201506663 D0 GB 201506663D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- therapy
- vivo delivery
- ion chelating
- chelating ligands
- ligands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/005—Crosslinking of cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/08—Cellulose derivatives
- C08L1/26—Cellulose ethers
- C08L1/28—Alkyl ethers
- C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506663.2A GB201506663D0 (en) | 2015-04-20 | 2015-04-20 | In-vivo delivery of ion chelating ligands for therapy |
PCT/EP2016/058811 WO2016170015A1 (en) | 2015-04-20 | 2016-04-20 | Epoxy derivatives of ion chelating ligands, their polymeric conjugates and medical uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506663.2A GB201506663D0 (en) | 2015-04-20 | 2015-04-20 | In-vivo delivery of ion chelating ligands for therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201506663D0 true GB201506663D0 (en) | 2015-06-03 |
Family
ID=53298845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1506663.2A Ceased GB201506663D0 (en) | 2015-04-20 | 2015-04-20 | In-vivo delivery of ion chelating ligands for therapy |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201506663D0 (en) |
WO (1) | WO2016170015A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115260401B (en) * | 2022-07-29 | 2023-11-03 | 天津绿菱气体有限公司 | Chelate resin for capturing electronic grade hexafluorobutadiene metal ions and preparation method thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5915325B2 (en) * | 1981-03-26 | 1984-04-09 | 工業技術院長 | Method for producing polyolefin film or fiber with crown ether ring |
JPS5915323B2 (en) * | 1981-08-28 | 1984-04-09 | 工業技術院長 | Method for producing alkali metal trap material |
DE3644346A1 (en) * | 1986-12-19 | 1987-05-21 | Saeulentechnik Dr Ing Herbert | Matrix-bound crown ether ligands as separating material in the affinity chromatography of nucleic acids |
DK169306B1 (en) * | 1989-06-14 | 1994-10-10 | Af 18 Juni 1990 As | Means for removing or inactivating unwanted components in blood or other extracellular body fluids and method of preparing dextran-O-carbonyl-benzo-18-crown-6 and of dextran-hydroxyethylbenzo-18-crown-6 |
US20050013925A1 (en) * | 2003-07-17 | 2005-01-20 | Melvin Cabey | Immobilization methods for organic molecules telomers and polymers on solid substrates |
US7390863B2 (en) * | 2005-08-30 | 2008-06-24 | Bausch & Lomb Incorporated | Polymeric materials having enhanced ion and water transport property and medical devices comprising same |
US8802074B2 (en) * | 2008-11-26 | 2014-08-12 | Board Of Regents, The University Of Texas System | Polymers functionalized with ion-specific recognition elements |
-
2015
- 2015-04-20 GB GBGB1506663.2A patent/GB201506663D0/en not_active Ceased
-
2016
- 2016-04-20 WO PCT/EP2016/058811 patent/WO2016170015A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2016170015A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254705A0 (en) | Combination therapy for cancer | |
ZA201802420B (en) | Combination therapy for treating malignancies | |
IL255060A0 (en) | Combination therapy for treating cancer | |
ZA201803166B (en) | Combination therapy for treating malignancies | |
HK1252425A1 (en) | Triazoles for the treatment of demyelinating diseases | |
ZA201802088B (en) | Combination therapy for treating malignancies | |
HK1254882A1 (en) | Combination therapies for treatment of cancer | |
IL258684A (en) | Combination therapy for treating malignancies | |
IL253461A0 (en) | Hydrogels for delivery of therapeutic compounds | |
GB2534986B (en) | Inhaler housing | |
HK1258128A1 (en) | Selection of patients for combination therapy | |
GB201506663D0 (en) | In-vivo delivery of ion chelating ligands for therapy | |
HK1254687A1 (en) | Combination therapy for cancer | |
HRP20210383T8 (en) | Combination therapy for cancer | |
HK1259026A1 (en) | Localized delivery of anti-fugetactic agent for treatment of cancer | |
SG11201801083UA (en) | Tumor therapeutic agent | |
GB201518805D0 (en) | Therapy | |
GB201506944D0 (en) | Therapeutic treatment | |
GB201511120D0 (en) | Cancer therapy | |
GB201417819D0 (en) | Agents for cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |